New insights into the biological therapy of Crohn’s disease

Bibliography

• FARMER RG, HAWK WA, TURNBULL RB JR: Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology (1975) 68:627–635.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN CN, BLANCHARD JF, RAWSTHORNE P, WAJDA A: Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am. J. Epidemiol. (1999) 149:916–924.
   PubMed Web of Science ®Google Scholar
• BINDER V, BOTH H, HANSEN PK, HENDRIKSEN C, KREINER S, TORP-PEDERSEN K: Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen, 1962 to 1978. Gastroenterology (1982) 83:563–568.
   PubMed Web of Science ®Google Scholar
• WYKE RJ, EDWARDS FC, ALLAN RN: Employment problems and prospects for patients with inflammatory bowel disease. Gut (1988) 29:1229–1235.
   PubMed Web of Science ®Google Scholar
• MALCHOW H, EWE K, BRANDES JW et al.: European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology (1984) 86:249–266.
   PubMed Web of Science ®Google Scholar
• MICHELASSI F, BALESTRACCI T, CHAPPELL R, BLOCK GE: Primary and recurrent Crohn's disease. Experience with 1379 patients. Ann. Surg (1991) 214:230–238.
   Google Scholar
• SCHWARTZ DA, PEMBERTON JH, SANDBORN WJ: Diagnosis and treatment of perianal fistulas in Crohn disease. Ann. Intern. Med. (2001) 135:906–918.
   PubMedGoogle Scholar
• REIMUND J-M, WITTERSHEIM C, DUMONT S et al.: Increased production of tumour necrosis factor-a, interleukin-113, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut (1996) 39:684–689.
   PubMedGoogle Scholar
• ROMAGNANI P, ANNUNZIATO F, BACCARI MC, PARRONCHI P: T cells and cytokines in Crohn's disease. Curr. Opin. Immunol. (1997) 9:793–799.
   PubMedGoogle Scholar
• KAPLAN D, SMITH D, HUANG R, YILDIRIM Z: Self-association of interleukin 2 bound to its receptor. FASEB J. (1995) 9:1096–1102.
   PubMedGoogle Scholar
• EIGLER A, SINHA B, HARTMANN G, ENDRES S: Taming TNF strategies to restrain this proinflammatory cytokine. Immunol Today (1997) 18:487–492.
   PubMedGoogle Scholar
• RUTGEERTS P, VAN ASSCHE G, VERMEIRE S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology (2004) 126:1593–1610.
   PubMed Web of Science ®Google Scholar
• BEST WR, BECKTEL JM, SINGLETON JW: Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology (1979) 77:843–846.
   PubMed Web of Science ®Google Scholar
• GAMMA C, GIUNTA M, ROSSELLI M, COTTONE M: Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology (1997) 113:1465–1473.
   PubMedGoogle Scholar
• URSING B, ALM T, BARANY F et al.: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the Cooperative Crohn's Disease Study in Sweden. II. Result. Gastroenterology (1982) 83:550–562.
   PubMed Web of Science ®Google Scholar
• COLOMBEL JF, LEMANN M, CASSAGNOU M et al.: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am. J. Gastroenterol (1999) 94:674–678.
   Google Scholar
• MUNKHOLM P, LANGHOLZ E, DAVIDSEN M BINDER V: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut (1994) 35:360–362.
   PubMed Web of Science ®Google Scholar
• MODIGLIANI R, COLOMBEL JF, DUPAS JL et al.: Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology (1996) 110:688–693.
   PubMedGoogle Scholar
• BIANCONE L, TOSTI C, FINA D et al.: Maintenance treatment of Crohn's disease. Aliment. Pharmacol Ther. (2003) 17\(Supp1.2) :31–37.
   Google Scholar
• SANDS BE, ANDERSON FH, BERNSTEIN CN et al.: Inffiximab maintenance therapy for fistulizing Crohn's disease. N Engl J. Med. (2004) 350:876–885.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, FAUBION WA: Biologics in inflammatory bowel disease: how much progress have we made? Gut (2004) 53:1366–1373.
   PubMed Web of Science ®Google Scholar
• PAPADAKIS KA, TARGAN SR: Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology (2000) 119:1148–1157.
   PubMed Web of Science ®Google Scholar
• BREESE E, MICHIE C, NICHOLLS S et al.: Tumor necrosis factor a-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology (1994) 106:1455–1466.
   PubMed Web of Science ®Google Scholar
• REINECKER HC, STEFFEN M, WITTHOEFT T et al.: Enhanced secretion of tumour necrosis factor-a IL-6, and IL-113 by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol (1993) 94:174–181.
   PubMed Web of Science ®Google Scholar
• NICHOLLS S, STEPHENS S, BRAEGGER CP, WALKER-SMITH JA, MACDONALD TT: Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J. Clin. PathoL (1993) 46:757–60.
   PubMed Web of Science ®Google Scholar
• LUGERING A. SCHMIDT M, LUGERING N, PAUELS HG, DOMSCHKE W, KUCHARZIK T: Inffiximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology (2001) 121:1145–1157.
   PubMed Web of Science ®Google Scholar
• HOVE T, VAN MONTFRANS C, PEPPELENBOSCH MP, VAN DEVENTER SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut (2002) 50:206–211.
   PubMedGoogle Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J. Med. (1997) 337:1029–1035.
   Google Scholar
• RUTGEERTS P, D'HAENS GR, TARGAN SR et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody to maintain remission in Crohn's disease. Gastroenterology (1999) 117:761–769.
   Google Scholar
• HANAUER SB, FEAGAN BG, LICHTENSTEIN et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 359:1541–1549.
   PubMed Web of Science ®Google Scholar
• COLOMBEL JF, LOFTUS EV JR, TREMAINE WJ et al.: The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology ( 2004) 126:19–31.
   PubMed Web of Science ®Google Scholar
• BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J. Med. (2003) 348:601–608.
   PubMed Web of Science ®Google Scholar
• STACK WA, MANN SD, ROY AJ et aL:Randomised controlled trial of CDP571 antibody to tumour necrosis factor-a in Crohn's disease. Lancet (1997) 349:521–524.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, FEAGAN BG, HANAUER SB et al.: An engineered human antibody to TNF 1CDP5711 for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology (2001) 120:1330–1338.
   PubMed Web of Science ®Google Scholar
• FEAGAN BG, SANDBORN WJ, BAKER J et al.: A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF 1CDP5711 for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology (2000) 118:A655.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, FEAGAN BG, RADFORD-SMITH G et cd: CDP571, a humanised monoclonal antibody to tumour necrosis factor a, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut (2004) 53:1485–1493.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, RUTGEERTS P, FEDORAK R et al.: CDP870, a humanized anti-TNF antibody fragment induces clinical response with remission in patients with active Crohn's disease. Gastroenterology (2003) 124(Suppl.):A61.
   Google Scholar
• SALFELD J, KAYMAKCALAN Z, TRACEY D, ROBERTS A, KAMEN R: Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum. (1998) 41:S57.
   Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER S, LOFTUS EV JR et al.: An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol (2004) 99:1984–1989.
   Google Scholar
• SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121:1088–1094.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, LEMMENS L, VAN ASSCHE G et al.: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment. Pharmacol. Ther. (2003)17:185–192.
   Google Scholar
• HOMMES D, VAN DEN BLINK B, PLASSE T et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology (2002) 122:7–14.
   Google Scholar
• NEURATH MF, PETTERSSON S, MEYER ZUM BUSCHENFELDE KH, STROBER W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NFKB abrogates established experimental colitis in mice. Nat. Med. (1996) 2:998–1004.
   PubMed Web of Science ®Google Scholar
• WESTERMANN B, ENGELHARDT B, HOFFMANN J: Migration of T-cells in vivo: molecular mechanisms and clinical implications. Ann. Intern. Med. (2001) 135:279–295.
   PubMed Web of Science ®Google Scholar
• HESTERBERG PE, WINSOR-HINES D, BRISKIN MJ et al.: Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin a4137. Gastroenterology (1996) 111:1373–1380.
   PubMed Web of Science ®Google Scholar
• GORDON FH, LAI CW, HAMILTON MI et al.: A randomized placebo-controlled trial of a humanized monoclonal antibody to a4 integrin in active Crohn's disease. Gastroenterology (2001) 121: 268–274. Expert Opin. Ther Patents (2005) 15(4)
   PubMed Web of Science ®Google Scholar
• GHOSH S, GOLDIN E, GORDON FH et al.: Natalizumab for active Crohn's disease. N Engl J. Med. (2003) 348:24–32.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, COLOMBEL J, ENNS Ret al.: Subanalyses from a phase 3 sudy on the evaluation of natalizumab in active Crohn's disease tharapy-1 (ENACT-1). Gut (2003) 52(Suppl.VI):A239.
   Google Scholar
• FEAGAN BG, GREENBERG G, WILD G et al.: Efficacy and safety of a humanized a4137 antibody in active Crohn's disease (CD). Gastroenterology (2003) 124:A25–A26.
   Google Scholar
• YACYSHYN BR, BOWEN-YACYSHYN MB et al: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 114:1133–1142.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, NIKOLAUS S, MALCHOW H et al.: Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology (2001) 120:1339–1346.
   PubMed Web of Science ®Google Scholar
• KUCHARZIK T, STOLL R, LUGERING N, DOMSCHKE W: Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin. Exp. Immunol (1995) 100:452–456.
   PubMed Web of Science ®Google Scholar
• FEDORAK RN, GANGL A, ELSON CO et al.: Recombinant human interleukin-10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology (2000) 119:1473–1482.
   PubMed Web of Science ®Google Scholar
• FEDORAK R, NIELSEN 0, WILLIAMS N et al.: Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn's disease. Gastroenterology (2001) 120:A127.
   Google Scholar
• SCHREIBER S, FEDORAK RN, NIELSEN OH et al.: Safety and efficacy of recombinant human interleukin-10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119:1461–1472.
   Google Scholar
• COLOMBEL JF, RUTGEERTS P, MALCHOW H et al.: Interleukin-10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut (2001) 49:42–46.
   PubMed Web of Science ®Google Scholar
• QIU BS, PFEIFFER CJ, KEITH JC JR: Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig. Dis. Sci (1996) 41:1625–1630.
   PubMed Web of Science ®Google Scholar
• SANDS BE, WINSTON BD, SALZBERG B et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment. Pharmacol Ther. (2002)16:399–406.
   PubMed Web of Science ®Google Scholar
• NEURATH MF, FUSS I, KELSALL BL, STUBER E, STROBER W. Antibodies to interleukin-12 abrogate established experimental colitis in mice. J. Exp. Med. (1995) 182:1281–1290.
   Google Scholar
• MANNON PJ, FUSS IJ, MAYER L et al:Anti-interleukin-12 antibody for active Crohn's disease. N Engl J. Med. (2004) 351:2069–2079.
   PubMed Web of Science ®Google Scholar
• HOSOKAWA T, KUSUGAMI K, INA K et al.: Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease J. Gastroenterol Hepatol (1999) 14:987–996.
   Google Scholar
• MITSUYAMA K, TOYONAGA A. SASAKI E et al.: Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut (1995) 36:45–49.
   Google Scholar
• ATREYA R, MUDTER J, FINOTTO S et al.: Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med (2000) 6:583–588.
   PubMed Web of Science ®Google Scholar
• ITO H, TAKAZOE M, FUKUDA Yet al:A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 126:989–996.
   PubMed Web of Science ®Google Scholar
• LUDWICZEK 0, VANNIER E, BORGGRAEFE I et al: Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin. Exp. Immunol (2004) 138:323–329.
   PubMed Web of Science ®Google Scholar
• COHEN S, HURD E, CUSH JJ et al: Treatment with interleukin-1 receptor antagonist in combination with methotrexate (MTX): results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:614–624.
   PubMed Web of Science ®Google Scholar
• ARNOTT ID, DRUMMOND HE, GHOSH S: Gut mucosal secretion of interleukin-10 and interleukin-8 predicts relapse in clinically inactive Crohn's disease. Dig. Dis. Sci. (2001) 46:402–409.
   PubMedGoogle Scholar
• COMINELLI F, NAST CC, DUCHINI A,LEE M: Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology (1992) 103:65–71.
   PubMed Web of Science ®Google Scholar